---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-145000"
form_type: "8-K"
ticker: "ANTX"
cik: "0001880438"
company_name: "AN2 Therapeutics, Inc."
filed_at: "2022-05-09T23:59:59+00:00"
generated_at: "2026-06-25T22:40:02.702281+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# AN2 Therapeutics appoints Maggie FitzPatrick as Class II director with option grant and cash retainer

## Summary
- Appointed May 5, 2022; also joins nominating and corporate governance committee.
- Initial stock option grant with grant-date value of $209,093 vesting monthly over 3 years.
- Annual cash director retainer of $39,000 paid quarterly for board and committee service.
- FitzPatrick brings experience from Johnson & Johnson, Cigna, and Exelon; also serves on VistaGen board.

## SEC filing metadata
- accession: 0001193125-22-145000
- form_type: 8-K
- ticker: ANTX
- cik: 0001880438
- company_name: AN2 Therapeutics, Inc.
- filed_at: 2022-05-09T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1880438/000119312522145000/0001193125-22-145000-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1880438/000119312522145000/d286325d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-145000
- JSON: https://secwatch.observer/filing/0001193125-22-145000.json
- Plain text: https://secwatch.observer/filing/0001193125-22-145000.txt

## Key facts
- Executive change
  Margaret (Maggie) M. FitzPatrick was appointed as Class II Director at AN2 Therapeutics, Inc..
  - Action: appointed
  - Role: Class II Director
  source text: On May 5, 2022, Margaret (Maggie) M. FitzPatrick was appointed to the board of directors (the “ Board ”) of AN2 Therapeutics, Inc., a Delaware corporation (the “ Company ”), as a Class II Director
  evidence_url: https://www.sec.gov/Archives/edgar/data/1880438/000119312522145000/0001193125-22-145000-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.